← Oncology Approval Tracker

FDA DECISION ·

Talzenna soft gelatin capsules

talazoparib tosylate · Pfizer

FDA approvalNew formulationBreast and prostate cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Liquid-filled soft gelatin capsules for adults with qualifying germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, or with enzalutamide for HRR-mutated metastatic castration-resistant prostate cancer.

LAMPGEN ANALYSIS

Why it matters

The FDA approved a soft gelatin capsule formulation for the existing indications and strengths, based on a bridge to the earlier hard capsules.

What research teams should watch

Identify the capsule formulation and exact strength in pharmacy records while continuing regimen-specific dose adjustment and blood count monitoring.

PRIMARY RECORDS

Sources